Phase 1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Advanced Pancreatic Cancer

Trial Profile

Phase 1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Advanced Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Pegargiminase (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Polaris Pharmaceuticals
  • Most Recent Events

    • 21 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Sep 2018.
    • 21 Feb 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2018.
    • 18 Aug 2017 Results published in the Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top